Catalent Inc., Johnson & Johnson's contract drug manufacturer, will boost its production capacity in Italy in order to be able to produce two times more doses of the pharmaceutical company's COVID-19 vaccine, The Wall Street Journal reported, citing people familiar with the matter.
Catalent is planning to launch its second production line in Anaghi, Italy, during the final quarter of the year, the report added.
According to the outlet, the move would help the European Union bridge the gap in the vaccine supply after AstraZeneca's jab came under intense scrutiny over jab's alleged link with an increased risk of blood clots.
